Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Astellas, Astrazeneca, Caladrius, Celltrion, Chromadex, CSL Behring, Eli Lilly, Emergent Biosolutions, Gilead Sciences, Glaxosmithkline, Grifols, Napajen, Noxopharm, Redhill Biopharma, Rigel, Seagen, Takeda, University of Oxford, Vir, Zai Lab.
Genome editing startup Edigene Inc. has raised RMB450 million ($67 million) in a series B financing round to move two of its programs for blood diseases into clinical trials. The financing round was led by 3H Health Investment, and supported by Sequoia Capital China, Alwin Capital and Kunlun Capital. Previous investors such as IDG Capital, Lilly Asia Venture, Huagai Capital and Green Pine Capital Partners also joined the round.
LONDON – Clinical care guidelines recommending the use of the HIV/AIDS combination lopinavir-ritonavir for the treatment of patients hospitalized with COVID-19 must now be updated, say the authors of a paper reporting the full results of a randomized U.K. study.
PERTH, Australia – Starpharma Holdings Ltd. completed a AU$45 million (US$32 million) placement to domestic and international investors that will see it advance its COVID-19 antiviral nasal spray. The treatment is based on the company’s antiviral dendrimer, SPL-7013.
With phase III vaccine trials nearly enrolled and data expected soon, a half-year of expedited development efforts, plus massive government funding may soon provide the ammunition needed to effectively stop the SARS-CoV-2 scourge of 2020.
HONG KONG – Xi’an, China-based Yufan Biotechnologies Co. Ltd. has partnered with Pittsburgh-based Abound Bio Inc. to discover and develop antibodies directing CAR T cells against cancer targets.
HONG KONG – Shanghai-based Bioshin Ltd., the Asia-Pacific arm of New Haven, Conn.-based Biohaven Pharmaceutical Holding Co. Ltd., has added $60 million to its war chest via a series A investment.
PERTH, Australia – Regenerative medicine company Mesoblast Ltd. saw its stock drop 37% on the news that it received an FDA complete response letter to its BLA for Ryoncil (remestemcel-L) for the treatment of pediatric steroid-refractory acute graft-vs.-host disease.
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Baylx, Carsgen, I-Mab, Innovation, Kyowa Kirin, Medimetriks, Neuren, Organicell, Otsuka, Taigen, Windtree.
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Algernon, Astrazeneca, Corvus, Curevac, Eisai, Enlivex, FSD, Harbour Biomed, Johnson & Johnson, Kancera, Kyowa Kirin, Medincell, Mei, Moderna, Regeneron, Revelation, Revive, Shanghai Junshi, Zai Lab.
RSS
